Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIMENSION: FATE-NK100 in advanced solid tumors
NCT03319459Phase 1Completed
- Sponsor
- Fate Therapeutics
- Start
- Jan 2018
- Primary completion
- May 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FATE-NK100 in solid tumor (advanced stage), breast cancer, gastric cancer (GC) and 2 more (3 arms), sponsored by Fate Therapeutics. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Started Jan 2018; status: completed.
02
Drugs
FATE-NK100
03
Conditions
solid tumor (advanced stage)breast cancergastric cancer (GC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03319459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319459.